Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments

PLoS One. 2019 Mar 12;14(3):e0209947. doi: 10.1371/journal.pone.0209947. eCollection 2019.

Abstract

Cannabis withdrawal upon discontinuation of long-term, heavy Cannabis use is reported in humans; however, methods to establish the nature and intensity of cannabinoid withdrawal, especially directly observable signs, have not been widely established. This study quantified activity in the home cage of rhesus monkeys and examined the extent to which activity can be used to quantify tolerance to and dependence on Δ9-tetrahydrocannabinol (Δ9-THC). Home-cage activity was measured in one group that received Δ9-THC (1 mg/kg s.c.) every 12 h (i.e., chronic Δ9-THC), and a second group that received Δ9-THC (0.1 mg/kg i.v.) once every 3 days (i.e., intermittent Δ9-THC). Treatment was temporarily discontinued in the chronic Δ9-THC group and the effects of rimonabant and Δ9-THC were examined in both groups. Activity counts were highest during the day (lights on 0600-2000 h) and were lower at night. Rimonabant (0.1-3.2 mg/kg i.v.) dose-dependently increased activity (maximum 20-fold) in the chronic Δ9-THC group but did not significantly alter activity in the intermittent Δ9-THC group. Δ9-THC (0.32-3.2 mg/kg i.v.) dose-dependently decreased activity counts (maximum 4-fold) in both groups but was somewhat more potent in the intermittent as compared with the Δ9-THC group. Discontinuation of Δ9-THC treatment resulted in an immediate (i.e., within 24 h) and time-related increase in activity. The time-related increase in home-cage activity upon abrupt discontinuation of chronic Δ9-THC treatment, as well as the effects of rimonabant to increase activity in monkeys receiving chronic, but not intermittent, Δ9-THC treatment, are consistent with signs of physical dependence on Δ9-THC in primates.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Intravenous
  • Animals
  • Disease Models, Animal
  • Dronabinol / adverse effects*
  • Drug Tolerance*
  • Female
  • Hallucinogens / adverse effects*
  • Hallucinogens / pharmacology
  • Humans
  • Macaca mulatta
  • Male
  • Motor Activity / drug effects*
  • Rimonabant / administration & dosage*
  • Rimonabant / pharmacology
  • Substance Withdrawal Syndrome / drug therapy*

Substances

  • Hallucinogens
  • Dronabinol
  • Rimonabant